Journal of Skin Cancer / 2011 / Article / Tab 2 / Research Article
Prognostic and Risk Factors in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma of the Trunk and Extremities Table 2 Univariate analysis of risk factors for lymph node metastasis in patients with locally advanced cutaneous squamous cell carcinoma of trunk and extremities.
Variables + Lymph node metastasis n (%) − Lymph node metastasis n (%) p Clinical Gender Male 16 (64.0%) 16 (53.3%) 0.584 Female 9 (36.0%) 14 (46.7%) Race Caucasian 22 (88.0%) 27 (90.0%) 1.000 African 3 (12.0%) 3 (10.0%) Ambient Rural 4 (16.0%) 5 (16.7%) 1.000 Urban 21 (84.0%) 25 (83.3%) Chronic Sun exposure Yes 14 (66.7%) 13 (72.2%) 0.742 No 7 (33.3%) 5 (27.8%) Anatomic location of primary tumor Lower extremities 8 (32.0%) 14 (46.7%) 0.151 Upper extremities 14 (56.0%) 9 (30.0%) Trunk 3 (12.0%) 7 (23.3%) Previous non neoplasic lesion Yes 7 (72.0%) 6 (20.0%) 0.537 No 18 (28.0%) 24 (80.0%) TNM Classification T3 13 (52.0%) 20 (66.7%) 0.286 T4 12 (48.0%) 10 (33.3%) Tumor length* Breslow 0–8 mm 14 (56.0%) 8 (44.5%) 0.533 Breslow >8 mm 10 (44.0%) 10 (55.5%) Mitosis/mm2 0–3 22 (44.9%) 27 (55.1%) 0.573 >3 3 (50.0%) 3 (50.0%) Tumor grade I 11 (44.0%) 14 (46.6%) 1.000 II-III 14 (56.0%) 16 (53.4%) Intratumoral lymphocitic infiltrate Negative 2 (8.0%) 10 (33.4%) 0.046 Positive 23 (92.0%) 20 (66.6%) Peritumoral lymphocitic infiltrate Negative 2 (8.0%) 7 (23.4%) 0.160 Positive 23 (92.0%) 23 (76.6%) Vascular infiltrate Negative 20 (80.0%) 28 (93.3%) 0.226 Positive 5 (20.0%) 2 ( 6.7%) Perineural infiltrate Negative 24 (96.0%) 30 (100.0%) 0.455 Positive 1 (4.0%) 0 (0.0%) Tumor markers EGFR Negative 17 (68.0%) 24 (80.0%) 0.363 Positive 8 (32.0%) 6 (20.0%) HER-2 Negative 25 (100%) 30 (100%) Not calculated Positive 0 0 HER-3 Negative 1 (4.0%) 6 (20.0%) 0.112 Positive 24 (96.0%) 24 (80.0%) HER-4 Negative 16 (65.0%) 12 (41.4%) 0.083 Positive 9 (35.0%) 17 (59.6%) Membrane E-cadherin Negative 12 (54.5%) 14 (46.7%) 0.779 Positive 10 (45.5%) 16 (53.3%) Cytoplasm E-cadherin Negative 17 (73.9%) 20 (46.6%) 0.764 Positive 6 (26.1%) 10 (63.4%) Podoplanin Negative 13 (52.0%) 19 (63.3%) 0.425 Positive 12 (48.0%) 11 (36.7%)
*Only 42 cases.